ABSTRACT
BACKGROUND: This AMEERA-2 study evaluated the pharmacokinetics, efficacy, and safety of the oral selective estrogen receptor degrader amcenestrant as a monotherapy with dose escalation in Japanese postmenopausal women with advanced estrogen receptor-positive and human epidermal growth factor receptor 2-negative breast cancer. METHODS: In this open-label, nonrandomized, phase I study, patients received amcenestrant 400 mg once daily (QD) (n = 7) and 300 mg twice daily (BID) (n = 3). The incidence of dose-limiting toxicities (DLT), recommended dose, maximum tolerated dose (MTD), pharmacokinetics, efficacy, and safety were assessed. RESULTS: No DLTs were observed and MTD was not reached in the 400 mg QD group. One DLT (grade 3 maculopapular rash) was reported in a patient treated with 300 mg BID. After repeated oral administration of either dosing regimen, steady state reached before day 8, without accumulation. Four out of 5 response-evaluable patients from 400 mg QD group achieved clinical benefit and showed tumor shrinkage. No clinical benefit was reported in the 300 mg BID group. Overall, most patients (8/10) experienced a treatment-related adverse event (TRAE), with skin and subcutaneous tissue disorders most commonly reported (4/10 patients). No ≥ grade 3 TRAE in 400 mg QD group and 1 grade 3 TRAE in 300 mg BID group were reported. CONCLUSIONS: Amcenestrant 400 mg QD has a favorable safety profile and has been selected as the recommended Phase II dose for monotherapy for evaluating the safety and efficacy of amcenestrant in a larger, global, randomized clinical trial of patients with metastatic breast cancer. TRIAL REGISTRATION: Clinical trial registration NCT03816839.
Subject(s)
Breast Neoplasms , Estrogen Antagonists , Female , Humans , Breast Neoplasms/drug therapy , Breast Neoplasms/genetics , Breast Neoplasms/pathology , East Asian People , Estrogen Antagonists/administration & dosage , Estrogen Antagonists/pharmacokinetics , Estrogen Antagonists/therapeutic use , Maximum Tolerated Dose , Receptors, Estrogen/genetics , Genes, erbB-2/genetics , Administration, Oral , Selective Estrogen Receptor Modulators/administration & dosage , Selective Estrogen Receptor Modulators/pharmacokinetics , Selective Estrogen Receptor Modulators/therapeutic useABSTRACT
The selective oestrogen receptor modulator (SERM) clomiphene is therapeutically used to induce ovulation. While prohibited as a doping agent in sports, it is frequently detected in sports drug testing urine samples. Few reports exist on clomiphene's (illicit) use in the farming industry to increase the egg production rate of laying hens, which creates a risk that eggs as well as edible tissue of these hens contain residues of clomiphene. To investigate the potential transfer of clomiphene into eggs and muscle tissue, laying hens were orally administered with clomiphene citrate at 10 mg/day for 28 days. To determine clomiphene residues in eggs, chicken breast and chicken thigh, the target analyte was extracted from homogenised material with acetonitrile and subjected to ultra-high performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS) analysis. The test method reached a limit of quantification (LOQ) of 1 µg/kg and was characterised concerning specificity, precision, trueness and linearity. Analyses were performed on whole egg, egg white and yolk separately, and chicken muscle from breast and thigh. Clomiphene was detectable in eggs two days after the beginning of the drug administration period. The drug concentrations increased to 10-20 µg per egg within one week, and after withdrawal of clomiphene, residues decreased after 4 days, but traces of clomiphene were still detectable until the end of the study (14 days after the last administration). In the chicken's muscle tissue, clomiphene levels up to 150 µg/kg (thigh) and 36 µg/kg (breast) were found. Six days after the last dose, tissue clomiphene concentrations fell below the LOQ. Overall, these results underline the concerns that clomiphene may be transferred into animal-derived food and future research will therefore need to focus on assessing and minimising the risk of unintentional adverse analytical findings in doping controls.
Subject(s)
Clomiphene/pharmacokinetics , Drug Residues/chemistry , Eggs/analysis , Estrogen Antagonists/pharmacokinetics , Meat/analysis , Muscle, Skeletal/chemistry , Administration, Oral , Animals , Chickens , Clomiphene/chemistry , Clomiphene/metabolism , Estrogen Antagonists/chemistry , Female , Food Contamination , OvipositionABSTRACT
BACKGROUND: Adjuvant endocrine therapies are known to induce undesirable adverse effects such as vasomotor, vaginal and musculoskeletal symptoms among breast cancer patients. Drugs used in these therapies are often metabolised by cytochrome P450 (CYP) enzymes, in which their metabolising activities can be modified by single nucleotide polymorphisms (SNP) in CYP genes and CYP genotypes. This review aims to explore whether SNPs or genotypes of CYP are associated with the occurrence, frequency and severity of vasomotor, vaginal and musculoskeletal symptoms in breast cancer patients on adjuvant endocrine therapies. METHODS: A literature review was conducted using five electronic databases, resulting in the inclusion of 14 eligible studies, and their findings were presented narratively. Selected items from the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) checklist were used for critical appraisal of the reporting quality of the included studies. RESULTS: Most of the included studies showed that SNPs or genotypes of CYP that modify its metabolising activity have no effect on the occurrence, frequency or severity of vasomotor symptoms, including hot flashes. One study showed no correlation of these genetic variations in CYP with musculoskeletal symptoms, and no data were available on the association between such genetic variations and vaginal symptoms. CONCLUSIONS: Overall, genetic variations in CYP have no effect on the experience of hot flashes among breast cancer patients. We recommend exploration of the link between the active metabolites of chemotherapeutic drugs and the molecules shown to affect the occurrence or severity of hot flashes, and the establishment of the relationship between such genetic variations and patients' experience of musculoskeletal and vaginal symptoms. Subgroup analyses based on patients' duration of adjuvant endocrine therapies in such studies are recommended.
Subject(s)
Antineoplastic Agents, Hormonal/adverse effects , Arthralgia/epidemiology , Breast Neoplasms/therapy , Cytochrome P-450 Enzyme System/genetics , Hot Flashes/epidemiology , Vagina/pathology , Antineoplastic Agents, Hormonal/pharmacokinetics , Arthralgia/chemically induced , Arthralgia/diagnosis , Arthralgia/genetics , Atrophy/chemically induced , Atrophy/diagnosis , Atrophy/epidemiology , Atrophy/genetics , Breast Neoplasms/genetics , Chemotherapy, Adjuvant/adverse effects , Chemotherapy, Adjuvant/methods , Cytochrome P-450 Enzyme System/metabolism , Estrogen Antagonists/adverse effects , Estrogen Antagonists/pharmacokinetics , Estrogens/metabolism , Female , Genetic Predisposition to Disease , Hot Flashes/chemically induced , Hot Flashes/diagnosis , Hot Flashes/genetics , Humans , Mastectomy , Observational Studies as Topic , Polymorphism, Single Nucleotide , Severity of Illness Index , Tamoxifen/adverse effects , Tamoxifen/analogs & derivatives , Tamoxifen/pharmacokinetics , Vagina/drug effectsSubject(s)
Drug Delivery Systems , Estrogen Antagonists/administration & dosage , Phospholipids/administration & dosage , Raloxifene Hydrochloride/administration & dosage , Animals , Apoptosis/drug effects , Caco-2 Cells , Cell Survival/drug effects , Drug Liberation , Erythrocytes/drug effects , Estrogen Antagonists/chemistry , Estrogen Antagonists/pharmacokinetics , Female , Hemolysis/drug effects , Humans , MCF-7 Cells , Molecular Docking Simulation , Phospholipids/chemistry , Phospholipids/pharmacokinetics , Raloxifene Hydrochloride/chemistry , Raloxifene Hydrochloride/pharmacokinetics , Rats, Sprague-Dawley , Reactive Oxygen Species/metabolismABSTRACT
In the present work, MCM-41 and MCM-48 type of nanoparticles were successfully engineered. Effect of nanosize and amine functionalization on drug release, in vitro intestinal absorption and in vivo pharmacokinetic behavior was investigated in a comprehensive manner. The tailor-made bare and surface decorated MCM-41 and MCM-48 were synthesized and evaluated for their mesoporous skeleton, pore size, particle size, surface area, zeta potential, etc. by nitrogen sorption, DLS, TEM, etc. Incorporation of raloxifene (RLF) was affirmed using optimized immersion-solvent evaporation technique and its success confirmed by DSC, IR, and XRD analysis. TGA analysis revealed higher %grafting of amine groups on the exterior and larger RLF encapsulation into mesoporous derivate. The detailed in vitro release study revealed SGF to be the most compatible media for RLF showing an initial burst release from pristine nanoparticles and a delayed release from surface coated nanoparticles. Furthermore, release kinetics model data demonstrated Weibull and Higuchi as the best fit models for bare and amine-functionalized nanoparticles respectively. Moreover, an in vitro permeability study on Caco-2 cell line revealed higher absorption by engineered nanoparticle as compared to pure RLF and its marketed formulation. The supremacy in the in vivo pharmacokinetic parameters of RLF-41 and RLF-48 was demonstrated with 3.33 and 3.50 times enhancement in the bioavailability of RLF with respect to RLF suspension. To sum up, the results obtained were superior and promising for synthesized nanoparticles and more precisely for MCM-48 amongst them.
Subject(s)
Drug Carriers/chemistry , Estrogen Antagonists/pharmacokinetics , Raloxifene Hydrochloride/pharmacokinetics , Administration, Oral , Animals , Biological Availability , Breast Neoplasms/drug therapy , Breast Neoplasms/pathology , Caco-2 Cells , Chemical Engineering/methods , Delayed-Action Preparations/administration & dosage , Delayed-Action Preparations/pharmacokinetics , Drug Liberation , Drug Screening Assays, Antitumor , Estrogen Antagonists/administration & dosage , Female , Humans , Intestinal Mucosa/metabolism , Mice , Nanoparticles/chemistry , Osteoporosis/drug therapy , Permeability , Raloxifene Hydrochloride/administration & dosage , Silicon Dioxide/chemistryABSTRACT
The work describes systematic development of nanomicellar cationic supersaturable self-nanoemulsifying drug delivery systems (CS-SNEDDS) for augmenting oral biopharmaceutical performance of raloxifene hydrochloride. Plain SNEDDS formulation containing Capryol 90, Cremophor RH 40, and Transcutol HP was optimized using D-optimal mixture design. SNEDDS were characterized for emulsification time, globule size, in vitro drug release, and ex vivo permeation. The CS-SNEDDS formulation was prepared from the optimized SNEDDS by adding oleylamine as the cationic charge inducer and HPMC as the polymeric precipitation inhibitor. Evaluation of CS-SNEDDS was carried out through in vitro cell line studies on Caco-2 and MCF-7 cells, in situ perfusion, and in vivo pharmacokinetic studies, which indicated significant improvement in biopharmaceutical attributes of the drug from CS-SNEDDS over plain drug.
Subject(s)
Drug Delivery Systems , Estrogen Antagonists/administration & dosage , Ethylene Glycols/administration & dosage , Nanoparticles/administration & dosage , Polyethylene Glycols/administration & dosage , Polymers/administration & dosage , Propylene Glycols/administration & dosage , Raloxifene Hydrochloride/administration & dosage , Animals , Biological Transport , Caco-2 Cells , Cell Survival/drug effects , Chemistry, Pharmaceutical , Drug Liberation , Emulsions , Estrogen Antagonists/chemistry , Estrogen Antagonists/pharmacokinetics , Ethylene Glycols/chemistry , Ethylene Glycols/pharmacokinetics , Humans , Hypromellose Derivatives/chemistry , Intestinal Mucosa/metabolism , MCF-7 Cells , Micelles , Models, Biological , Nanoparticles/chemistry , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Polymers/chemistry , Polymers/pharmacokinetics , Propylene Glycols/chemistry , Propylene Glycols/pharmacokinetics , Raloxifene Hydrochloride/chemistry , Raloxifene Hydrochloride/pharmacokinetics , Rats, Sprague-DawleyABSTRACT
The present study aims at the development of cholesterol based lipopolymeric nanoparticles for improved entrapment, better cell penetration and improved pharmacokinetics of Tamoxifen (TMX). Self-assembling cholesterol grafted lipopolymer, mPEG-b-(CB-{g-chol}-co-LA) was synthesized from poly(ethyleneglycol)-block-2-methyl-2-carboxyl-propylenecarboxylic acid-co-poly (l-lactide) [mPEG-b-(CB-{g-COOH}-co-LA)] copolymer followed by carbodiimide coupling for attaching cholesterol. Lipopolymeric nanoparticles were prepared using o/w solvent evaporation technique, which were subsequently characterized to determine its particle size, entrapment efficiency, release pattern and compared with mPEG-PLA nanoparticles. Further, in order to assess the in vitro efficacy, cytotoxicity studies, uptake, apoptosis assay and cell cycle analysis were performed in breast cancer cell lines (MCF-7 and 4T1). Finally, the pharmacokinetic profile of TMX loaded mPEG-b-(CB-{g-chol}-co-LA) lipopolymeric nanoparticles was also performed. TMX loaded lipopolymeric nanoparticles of particle size 151.25⯱â¯3.74 (PDI 0.123) and entrapment efficiency of 73.62⯱â¯3.08% were formulated. The haemolytic index, protein binding and in vitro drug release of the optimized nanoparticles were found to be comparable to that of the TMX loaded mPEG-PLA nanoparticles. Lipopolymeric nanoparticles demonstrated improved IC50 values in breast cancer cells (22.2⯵M in 4T1; 18.8⯵M in MCF-7) than free TMX (27.6⯵M and 23.5⯵M respectively) and higher uptake efficiency. At IC50 values, TMX loaded lipopolymeric nanoparticles induced apoptosis and cell cycle arrest (G0/G1 phase) to similar extent as that of free drug. Pharmacokinetic studies indicated â¼2.5-fold increase in the half-life (t1/2) (pâ¯<â¯0.001) and â¼2.7-fold (pâ¯<â¯0.001) increase in the mean residence time (MRT) of TMX following incorporation into lipopolymeric nanoparticles. Thus, mPEG-b-(CB-{g-chol}-co-LA) lipopolymeric nanoparticles offer a more promising approach for delivery of Tamoxifen in breast cancer by improving drug internalization and prolonging the mean residence time of the drug indicating possibility of dose reduction and hence bypassing the adverse effects of TMX therapy.
Subject(s)
Antineoplastic Agents, Hormonal/administration & dosage , Cholesterol/administration & dosage , Drug Carriers/administration & dosage , Estrogen Antagonists/administration & dosage , Nanoparticles/administration & dosage , Polyesters/administration & dosage , Polyethylene Glycols/administration & dosage , Tamoxifen/administration & dosage , Animals , Antineoplastic Agents, Hormonal/chemistry , Antineoplastic Agents, Hormonal/pharmacokinetics , Apoptosis/drug effects , Biological Transport , Cell Cycle Checkpoints/drug effects , Cell Line, Tumor , Cell Survival/drug effects , Cholesterol/chemistry , Cholesterol/pharmacokinetics , Drug Carriers/chemistry , Drug Carriers/pharmacokinetics , Drug Liberation , Erythrocytes/drug effects , Estrogen Antagonists/chemistry , Estrogen Antagonists/pharmacokinetics , Hemolysis/drug effects , Humans , Mice , Nanoparticles/chemistry , Polyesters/chemistry , Polyesters/pharmacokinetics , Polyethylene Glycols/chemistry , Polyethylene Glycols/pharmacokinetics , Tamoxifen/chemistry , Tamoxifen/pharmacokineticsABSTRACT
OBJECTIVES: This study was designed to demonstrate the potential of novel α-lipoic acid-stearylamine (ALA-SA) conjugate-based solid lipid nanoparticles in modulating the pharmacokinetics and hepatotoxicity of tamoxifen (TMX). METHODS: α-lipoic acid-stearylamine bioconjugate was synthesized via carbodiimide chemistry and used as a lipid moiety for the generation of TMX-loaded solid lipid nanoparticles (TMX-SLNs). TMX-SLNs were prepared by solvent emulsification-diffusion method and optimized for maximum drug loading using rotatable central composite design. The optimized TMX-SLNs were stabilized using 10% w/w trehalose as cryoprotectant. In addition, pharmacokinetics and hepatotoxicity of freeze-dried TMX-SLNs were also evaluated in Sprague Dawley rats. KEY FINDINGS: Initial characterization with transmission electron microscopy revealed spherical morphology with smooth surface having an average particle size of 261.08 ± 2.13 nm. The observed entrapment efficiency was 40.73 ± 2.83%. In-vitro release study showed TMX release was slow and pH dependent. Pharmacokinetic study revealed a 1.59-fold increase in relative bioavailability as compared to TMX suspension. A decrease in hepatotoxicity of TMX is evidenced by the histopathological evaluation of liver tissues. CONCLUSIONS: α-lipoic acid-stearylamine conjugate-based SLNs have a great potential in enhancing the oral bioavailability of poorly soluble drugs like TMX. Moreover, this ALA-SA nanoparticulate system could be of significant value in long-term anticancer therapy with least side effects.
Subject(s)
Amines/chemistry , Chemical and Drug Induced Liver Injury/prevention & control , Drug Carriers , Estrogen Antagonists/pharmacokinetics , Nanoparticles , Tamoxifen/pharmacokinetics , Thioctic Acid/chemistry , Administration, Oral , Animals , Biological Availability , Chemical and Drug Induced Liver Injury/etiology , Chemical and Drug Induced Liver Injury/pathology , Cryoprotective Agents/chemistry , Drug Compounding , Drug Stability , Estrogen Antagonists/administration & dosage , Estrogen Antagonists/chemistry , Estrogen Antagonists/toxicity , Female , Freeze Drying , Hydrogen-Ion Concentration , Nanotechnology , Particle Size , Rats, Sprague-Dawley , Solubility , Solvents/chemistry , Surface Properties , Surface-Active Agents/chemistry , Tamoxifen/administration & dosage , Tamoxifen/chemistry , Tamoxifen/toxicity , Technology, Pharmaceutical/methods , Thioctic Acid/analogs & derivatives , Trehalose/chemistryABSTRACT
Clomiphene has growth-inhibitory effects of breast cancer cells, clomiphene was successfully labeled with (125)I via direct electrophilic substitution reaction with labeling yield 97%. It was obtained at optimum substrate amount of 0.5mg, Chloramine-T was used as an oxidizing agent at optimum amount of 25µg. Labeling reactions was done at pH 5 at ambient temperature. This study showed good in vitro and in vivo stability of the (125)I-clomiphene. The radiolabeled compound showed high ascetic fluid uptake of 18.12±0.27% at 30min post-injection. Solid tumor uptake of (125)I-clomiphene was 12.48±0.32% at 30min post-injection. This data revealed the localization of tracer in tumor tissue with high percent sufficient to use (125)I-clomiphene as a promising tool for the diagnosis of breast cancer.
Subject(s)
Breast Neoplasms/diagnostic imaging , Clomiphene/pharmacokinetics , Estrogen Antagonists/pharmacokinetics , Cell Line, Tumor , Chloramines , Humans , Isotope Labeling , Tissue Distribution , Tosyl CompoundsABSTRACT
The clinical usefulness of assessing the enzymatic activity of CYPD6 in patients taking tamoxifen had been longly debated. In favour of preemptive evaluation of phenotypic profile of patients is the strong pharmacologic rationale, being that the formation of endoxifen, the major and clinically most important metabolite of tamoxifen, is largely dependent on the activity of CYP2D6. This enzyme is highly polymorphic for which the activity is largely depending on genetics, but that can also be inhibited by a number of drugs, i.e. antidepressants, which are frequently used in patients with cancer. Unfortunately, the clinical trials that have been published in the last years are contradicting each other on the association between CYP2D6 and significant clinical endpoints, and for this reason CYP2D6 genotyping is at present not generally recommended. Despite this, the CYP2D6 genotyping test for tamoxifen is available in many laboratories and it may still be an appropriate test to use it in specific cases.
Subject(s)
Cytochrome P-450 CYP2D6/genetics , Estrogen Antagonists/therapeutic use , Tamoxifen/therapeutic use , Animals , Cytochrome P-450 CYP2D6/metabolism , Drug Interactions , Estrogen Antagonists/pharmacokinetics , Genotype , Glucuronosyltransferase/genetics , Glucuronosyltransferase/metabolism , Humans , Liver-Specific Organic Anion Transporter 1/genetics , Liver-Specific Organic Anion Transporter 1/metabolism , Tamoxifen/pharmacokineticsABSTRACT
The antiestrogenic drug tamoxifen is widely used in the treatment of estrogen receptor-α-positive breast cancer and substantially decreases recurrence and mortality rates. However, high interindividual variability in response is observed, calling for a personalized approach to tamoxifen treatment. Tamoxifen is bioactivated by cytochrome P450 (CYP) enzymes such as CYP2B6, CYP2C9, CYP2C19, CYP2D6 and CYP3A4/5, resulting in the formation of active metabolites, including 4-hydroxy-tamoxifen and endoxifen. Therefore, polymorphisms in the genes encoding these enzymes are proposed to influence tamoxifen and active tamoxifen metabolites in the serum and consequently affect patient response rates. To tailor tamoxifen treatment, multiple studies have been performed to clarify the influence of polymorphisms on its pharmacokinetics and pharmacodynamics. Nevertheless, personalized treatment of tamoxifen based on genotyping has not yet met consensus. This article critically reviews the published data on the effect of various genetic polymorphisms on the pharmacokinetics and pharmacodynamics of tamoxifen, and reviews the clinical implications of its findings. For each CYP enzyme, the influence of polymorphisms on pharmacokinetic and pharmacodynamic outcome measures is described throughout this review. No clear effects on pharmacokinetics and pharmacodynamics were seen for various polymorphisms in the CYP encoding genes CYP2B6, CYP2C9, CYP2C19 and CYP3A4/5. For CYP2D6, there was a clear gene-exposure effect that was able to partially explain the interindividual variability in plasma concentrations of the pharmacologically most active metabolite endoxifen; however, a clear exposure-response effect remained controversial. These controversial findings and the partial contribution of genotype in explaining interindividual variability in plasma concentrations of, in particular, endoxifen, imply that tailored tamoxifen treatment may not be fully realized through pharmacogenetics of metabolizing enzymes alone.
Subject(s)
Tamoxifen/pharmacology , Tamoxifen/pharmacokinetics , Breast Neoplasms/drug therapy , Breast Neoplasms/metabolism , Estrogen Antagonists/pharmacokinetics , Estrogen Antagonists/pharmacology , Female , Humans , Precision Medicine/methodsABSTRACT
The impact of gastrointestinal (GI) processing and first pass metabolism on danazol oral bioavailability (BA) was evaluated after administration of self-emulsifying drug delivery systems (SEDDS) in the rat. Danazol absolute BA was determined following oral and intraduodenal (ID) administration of LFCS class IIIA medium chain (MC) formulations at high (SEDDSH-III) and low (SEDDSL-III) drug loading and a lipid free LFCS class IV formulation (SEDDS-IV). Experiments were conducted in the presence and absence of ABT (1-aminobenzotriazole) to evaluate the effect of first pass metabolism. A series of modified in vitro lipolysis tests were developed to better understand the in vivo processing of SEDDS in the rat. Danazol BA was low (<13%) following oral and ID administration of either SEDDS. Increasing drug loading, ID rather than oral administration, and administration of SEDDS-IV rather than SEDDS-III led to higher oral BA. After pretreatment with ABT, however, danazol oral BA significantly increased (e.g., 60% compared to 2% after administration of SEDDSL-III), no effect was observed on increasing drug loading, and differences between SEDDS-III and -IV were minimal. In vitro digestion models based on the lower enzyme activity and lower dilution conditions expected in the rat resulted in significantly reduced danazol precipitation from SEDDS-III or SEDDS-IV on initiation of digestion. At the doses administered here (4-8 mg/kg), the primary limitation to danazol oral BA in the rat was first pass metabolism, and the fraction absorbed was >45% after oral administration of SEDDS-III or SEDDS-IV. In contrast, previous studies in dogs suggest that danazol BA is less dependent on first pass metabolism and more sensitive to changes in formulation processing. In vitro digestion models based on likely rat GI conditions suggest less drug precipitation on formulation digestion when compared to equivalent dog models, consistent with the increases in in vivo exposure (fraction absorbed) seen here in ABT-pretreated rats.
Subject(s)
Chemistry, Pharmaceutical , Danazol/pharmacology , Estrogen Antagonists/pharmacology , Intestinal Absorption/drug effects , Intestines/drug effects , Lipids/chemistry , Administration, Oral , Animals , Biological Availability , Danazol/administration & dosage , Danazol/pharmacokinetics , Digestion , Dogs , Drug Carriers , Drug Delivery Systems , Duodenum/drug effects , Estrogen Antagonists/administration & dosage , Estrogen Antagonists/pharmacokinetics , In Vitro Techniques , Rats , Solubility , Tissue Distribution , Triazoles/metabolismABSTRACT
For over 20years, stealth drug delivery has been synonymous with nanoparticulate formulations and intravenous dosing. The putative determinants of stealth in these applications are the molecular weight and packing density of a hydrophilic polymer (commonly poly(ethylene glycol) (PEG)) that forms a steric barrier at the surface of the nanoparticle. The current study examined the potential translation of the concepts learned from stealth technology after intravenous administration to oral drug delivery and specifically, to enhance drug exposure after administration of oral lipid-based formulations (LBFs) containing medium-chain triglycerides (MCT). MCT LBFs are rapidly digested in the gastrointestinal tract, typically resulting in losses in solubilisation capacity, supersaturation and drug precipitation. Here, non-ionic surfactants containing stealth PEG headgroups were incorporated into MCT LBFs in an attempt to attenuate digestion, reduce precipitation risk and enhance drug exposure. Stealth capabilities were assessed by measuring the degree of digestion inhibition that resulted from steric hindrance of enzyme access to the oil-water interface. Drug-loaded LBFs were assessed for maintenance of solubilising capacity during in vitro digestion and evaluated in vivo in rats. The data suggest that the structural determinants of stealth LBFs mirror those of parenteral formulations, i.e., the key factors are the molecular weight of the PEG in the surfactant headgroup and the packing density of the PEG chains at the interface. Interestingly, the data also show that the presence of labile ester bonds within a PEGylated surfactant also impact on the stealth properties of LBFs, with digestible surfactants requiring a PEG Mw of ~1800g/mol and non-digestible ether-based surfactants ~800g/mol to shield the lipidic cargo. In vitro evaluation of drug solubilisation during digestion showed stealth LBFs maintained drug solubilisation at or above 80% of drug load and reduced supersaturation in comparison to digestible counterparts. This trend was also reflected in vivo, where the relative bioavailability of drug after administration in two stealth LBFs increased to 120% and 182% in comparison to analogous digestible (non-stealth) formulations. The results of the current study indicate that self-assembled "stealth" LBFs have potential as a novel means of improving LBF performance.
Subject(s)
Danazol/administration & dosage , Estrogen Antagonists/administration & dosage , Polyethylene Glycols/metabolism , Administration, Oral , Animals , Biological Availability , Chemistry, Pharmaceutical , Danazol/pharmacokinetics , Drug Delivery Systems , Estrogen Antagonists/pharmacokinetics , Male , Polyethylene Glycols/chemistry , Rats , Rats, Sprague-Dawley , Solubility , Surface-Active Agents/chemistry , Surface-Active Agents/metabolism , Triglycerides/chemistry , Triglycerides/metabolismABSTRACT
The main aim of this study was to improve the oral bioavailability of raloxifene (RXF), a selective estrogen receptor modulator, by incorporation into solid lipid nanoparticles (SLN). RXF-loaded SLN was prepared by homogenization-sonication technique and characterized through physicochemical, pharmacokinetic, and cytotoxicity studies. The optimized SLN formulation exhibited a spherical shape with average size around 140 nm, easing its transport across the lymphatic system. Augmentation in the profiles of C(max) (308%) and AUC (270%) indicated a significant enhancement in the rate and extent of bioavailability by SLN formulations compared to free drug. In vitro cytotoxicity study performed in NIH-3T3 cells revealed that RXF-SLN was cytocompatible, and SLN remained unchanged during the freeze-drying process. Furthermore, the optimized formulation was quite stable at room temperature for more than two months, exemplifying its superior performance. In conclusion, SLN provides a promising platform for the pronounced enhancement of RXF bioavailability.
Subject(s)
Lipids/chemistry , Nanocapsules/chemistry , Raloxifene Hydrochloride/administration & dosage , Raloxifene Hydrochloride/pharmacokinetics , Administration, Oral , Animals , Diffusion , Drug Compounding/methods , Estrogen Antagonists/administration & dosage , Estrogen Antagonists/chemistry , Estrogen Antagonists/pharmacokinetics , Macromolecular Substances/chemistry , Male , Materials Testing , Metabolic Clearance Rate , Molecular Conformation , Nanocapsules/administration & dosage , Particle Size , Raloxifene Hydrochloride/blood , Rats , Rats, Sprague-Dawley , Surface PropertiesABSTRACT
Microspheres of different proportions of poly-(D,L-lactide-co-glycolide) and poly-(D,L-lactide) were formulated by spray drying as a drug-delivery system for the treatment of breast cancer with tamoxifen. These systems had been evaluated previously in vitro and showed very positive results that have led to further assessment in vivo. This work evaluates the performance of these systems in an organism by carrying out a study in female Wistar rats. Microspheres were subcutaneously injected into the back of rats for the assessment of not only the biocompatibility but also the release of the drug contained and its biodistribution. As, in vitro, these systems could release the drug under physiological conditions; different plasma concentrations of tamoxifen and one of its metabolites, 4-hydroxy-tamoxifen, were achieved depending on the polymer composition. Microspheres could reduce the accumulation of the drug in different nontarget organs and presented good biocompatibility.
Subject(s)
Antineoplastic Agents, Hormonal/pharmacokinetics , Estrogen Antagonists/pharmacokinetics , Polyesters/chemistry , Polyglactin 910/chemistry , Tamoxifen/pharmacokinetics , Animals , Antineoplastic Agents, Hormonal/administration & dosage , Breast Neoplasms/drug therapy , Drug Carriers , Estrogen Antagonists/administration & dosage , Female , Microspheres , Rats , Rats, Wistar , Tamoxifen/administration & dosage , Tissue DistributionABSTRACT
PURPOSE: To explore the possibility that age-related changes in physiology may result in differences in drug bioavailability after oral administration of lipid based formulations of danazol. METHODS: Danazol absorption from lipid formulations with increasing drug load was examined in younger (9 months) and older (8 years) beagles. Age related changes to hepatic function were assessed via changes to systemic clearance and serum bile acid concentrations. Changes to lipolytic enzyme activity and intestinal bile salt concentration were evaluated using in vitro lipolysis. RESULTS: Drug exposure increased linearly with dose in younger animals. In older animals, bioavailability increased with increasing dose to a tipping point, beyond which bioavailability reduced (consistent with initiation of precipitation). No differences in hepatic function were apparent across cohorts. Changes to enzyme concentrations in lipolysis studies had little impact on drug precipitation/solubilisation. In contrast, higher bile salt concentrations better supported supersaturation at higher drug loads. CONCLUSIONS: Differences in animal cohort can have a significant impact on drug absorption from lipid based formulation. For danazol, bioavailability was enhanced under some circumstances in older animals. In vitro experiments suggest that this was unlikely to reflect changes to metabolism or lipolysis, but might be explained by increases in luminal bile salt/phospholipid concentrations in older animals.
Subject(s)
Aging/metabolism , Bile Acids and Salts/pharmacology , Danazol/administration & dosage , Danazol/pharmacokinetics , Estrogen Antagonists/administration & dosage , Estrogen Antagonists/pharmacokinetics , Animals , Bile Acids and Salts/chemistry , Biological Availability , Chemistry, Pharmaceutical , Dogs , Gallbladder/growth & development , Gallbladder/metabolism , Liver/enzymology , Liver/growth & development , Liver/physiology , Liver Function Tests , Male , ThermodynamicsABSTRACT
Raloxifene hydrochloride (RL-HCL) is an orally selective estrogen receptor modulator (SERM) with poor bioavailability of nearly 2% due to its poor aqueous solubility and extensive first pass metabolism. In order to improve the oral bioavailability of raloxifene, raloxifene loaded solid lipid nanoparticles (SLN) have been developed using Compritol 888 ATO as lipid carrier and Pluronic F68 as surfactant. Raloxifene loaded SLN were prepared by solvent emulsification/evaporation method, and different concentrations of surfactant, and homogenization speed were taken as process variables for optimization. SLN were characterized for particle size, zeta potential, entrapment efficiency, surface morphology, and crystallinity of lipid and drug. In vitro drug release studies were performed in phosphate buffer of pH 6.8 using dialysis bag diffusion technique. Particle sizes of all the formulations were in the range of 250 to 1406 nm, and the entrapment efficiency ranges from 55 to 66%. FTIR and DSC studies indicated no interaction between drug and lipid, and the XRD spectrum showed that RL-HCL is in amorphous form in the formulation. In vitro release profiles were biphasic in nature and followed Higuchi model of release kinetics. Pharmacokinetics of raloxifene loaded solid lipid nanoparticles after oral administration to Wistar rats was studied. Bioavailability of RL-HCL loaded SLN was nearly five times than that of pure RL-HCL.
Subject(s)
Estrogen Antagonists/chemistry , Estrogen Antagonists/pharmacokinetics , Nanoparticles/chemistry , Raloxifene Hydrochloride/chemistry , Raloxifene Hydrochloride/pharmacokinetics , Animals , Biological Availability , Delayed-Action Preparations/chemistry , Delayed-Action Preparations/pharmacokinetics , Delayed-Action Preparations/pharmacology , Drug Evaluation, Preclinical , Estrogen Antagonists/pharmacology , Male , Raloxifene Hydrochloride/pharmacology , Rats , Rats, WistarABSTRACT
The aim of this work was to evaluate the feasibility of delivering transdermally a series of highly lipophilic compounds (log P ~4-7), comprising several selective oestrogen receptor modulators and a modified testosterone (danazol). The maximum fluxes of the drugs were predicted theoretically using the modified Potts & Guy algorithm (to determine the permeability coefficient (kp) from water) and the calculated aqueous solubilities. The correction provided by Cleek & Bunge took into account the contribution of the viable epidermal barrier to the skin permeation of highly lipophilic compounds. Experimental measurements of drug fluxes from saturated hydroalcoholic solutions were determined in vitro through excised pig skin. Overall, the predicted fluxes were in good general agreement (within a factor of 10) with the experimental results. Most of the experimental fluxes were greater than those predicted theoretically suggesting that the 70:30 v/v ethanol-water vehicle employed may have had a modest skin penetration enhancement effect. This investigation shows that the transdermal fluxes of highly lipophilic compounds can be reasonably predicted from first principles provided that the viable epidermis, underlying the stratum corneum, is included as a potentially important contributor to the skin's overall barrier function. Furthermore, the absolute values of the measured fluxes, when considered in parallel with previous clinical studies, indicate that it might be feasible to topically deliver a therapeutically useful amount of some of the compounds considered to treat cancerous breast tissue.
Subject(s)
Danazol/administration & dosage , Estrogen Antagonists/administration & dosage , Selective Estrogen Receptor Modulators/administration & dosage , Administration, Cutaneous , Algorithms , Animals , Danazol/pharmacokinetics , Drug Delivery Systems/methods , Estrogen Antagonists/pharmacokinetics , Models, Biological , Permeability , Selective Estrogen Receptor Modulators/pharmacokinetics , Skin/metabolism , Skin Absorption , SwineABSTRACT
PURPOSE: Evaluate the impact of luminal micellar phase on passive permeability of five lipophilic (1.9 ≤ clogP ≤ 9.0) small molecules using biorelevant media and evaluate the impact of luminal coarse lipid particles on danazol permeability after oral administration of a triglyceride solution to fed adults using PAMPA. METHODS: Permeability of carbamazepine, furosemide, danazol, and Compound A was evaluated using Prisma™ HT, FaSSIF-V2, and FeSSIF-V2 in the donor compartment. Compound B could not be tested using Prisma™ HT, due to negligible solubility. Individual intestinal aspirates collected after administration of danazol solution in the olive oil portion of a meal and corresponding micellar phases were subjected to PAMPA. Commercially available Acceptor Sink Buffer was used in all cases. RESULTS: Unlike with furosemide (under constant pH) and Compound B, permeability of carbamazepine, danazol, and Compound A steadily decreased in the presence of increasing micelle concentration of media. Danazol permeability from aspirates was reduced compared to that from micellar phases; fluxes were similar. CONCLUSIONS: Using PAMPA, the impact of luminal micellar phase on passive permeability of lipophilic molecules varies with the molecule. After administration of a triglyceride solution of danazol, high danazol concentrations in coarse lipid particles balance in terms of drug flux the reduced permeability.